UnitedHealth Group has launched a temporary infusion center in Minnetonka to provide antibody treatments that could help a subset of COVID-19 patients avoid hospitalizations.
Many hospitals and clinics in Minnesota already provide the infusions, but the offering by the Minnetonka-based health care giant is unusual in its home state.
In Las Vegas, where UnitedHealth Group's Optum division already operates a large multi-specialty clinic, the company's new dedicated space for antibody infusions fits with its broader push into direct patient care. The infusion center in the Twin Cities, meanwhile, is a "pop-up" option, officials said, that's meant simply to respond to the public health crisis — not a first step toward a long-term outpost for clinical care.
Located near the UnitedHealth Group corporate campus, the new infusion center is part of a broader push for research and development work related to the pandemic at a unit called OptumLabs.
"I anticipate that there will be more clinics that there will be a need for — and I hope that OptumLabs is going to step up and set up those access points," said Dr. Dan Griffin, a senior infectious disease fellow at UnitedHealth Group who also works at the company's large medical group in New York.
"Not everyone is going to decide to get vaccinated," Griffin said. "So, we don't think COVID is going to vanish — we don't think it's going to zero. ... We're expecting there to continue to be COVID cases in the fall, in the winter."
The treatment consists of "monoclonal antibodies," which are laboratory-made proteins that block the pandemic virus from attaching to and entering human cells.
Former President Donald Trump was treated with monoclonal antibodies when he got sick with COVID-19 last year.